Posted by Michael Wonder on 31 Jul 2016
CADTH recommends reimbursement of Eylea
27 July 2016 - CADTH has recommended that Bayer's aflibercept (Eylea) be reimbursed in Canada.
The Canadian Drug Expert Committee has recommended that aflibercept be reimbursed for the treatment of branch retinal vein occlusion with certain clinical criteria and conditions.
